陈鹏于2014年6月本科毕业于南昌大学药学院；2017年7月硕士毕业于南方医科大学药学院；2017.07-2020.08在东阳光药物研发有限公司从事有机合成研究员工作。于2020年9月进入中山大学药学院(深圳)高理钱老师课题组开始研究生期间的学习，为中山大学2020级在读博士研究生。

E-mail: chenp268@mail2.sysu.edu.cn

Publications (After joining SYSU) （# Equal contribution, * Corresponding author）

1. P. Chen#, J. Sun#, C. Zhu#, G. Tang*, W. Wang, M. Xu, M. Xiang, C.-J. Zhang, Z.-M. Zhang*, L. Gao*, S. Q. Yao*, “Cell-active, reversible and irreversible covalent inhibitors that selectively target the catalytic lysine of BCR-ABL kinase”, Angew. Chem. Int. Ed. (2022), 61(26):e202203878. (IF 15.336, 中科院1区，Top期刊) 

2.  P. Chen#, L. Lou #,  B. Sharma, M. Li, C. Xie, F. Yang , Y. Wu*, Q. Xiao *, L. Gao*, “Recent advances on PKM2 modulators including inhibitors and activators in biomedical applications",Current Medicinal Chemistry (2023),  in press, DOI: 10.2174/0929867331666230714144851. 

3.P. Chen#, G. Tang#, *, C. Zhu#, J. Sun, X. Wang, M. Xiang, H. Huang, W. Wang, L. Li, Z. Zhang*, L. Gao*, S.Q. Yao*, “ 2-Ethynylbenzaldehyde (EBA)-based, lysine-targeting irreversible covalent inhibitors for protein kinases and non-kinases”, J. Am Chem. Soc. (2023), 145 (7)，3844-3849. (IF16.383, 中科院1区，Top Journal).

4. J. Sun#, L. Lou#, C-J Zhu#, P. Chen, G. Tang, M. Gu, S. Xia, X. Dong,* Z.-M. Zhang,* L. Gao,* S.Q. Yao,* Q. Xiao*,“Chemical Evolution to Improve Bcr-Abl Kinase Inhibitors via Covalent and Pro-/Dual-drug Targeting Strategies”, XXXX (2023), submitted.

5. P. Chen#, J. Sun#, L. Wang#, M. Xiang, M. Gu, F. Miao, X. Wang, L. Duan, P. Yuan, Z.-M. Zhang*, X. Lu*, L. Gao*, S.Q. Yao*, “Cell-Active, Arginine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Non-Kinases”, XXXX (2023), submitted.

6. X. Wang, J. Sun, H. Huang, G. Tang, P. Chen, M. Xiang, L. Li, Z.-M. Zhang,* L. Gao,* S.Q. Yao*, “Kinase Inhibition via Small Molecule-Induced Intramolecular Protein Cross-Linking”, XXXX (2024), submitted.